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Abstract
Background: Disorders of the oxidative phosphorylation (OXPHOS) system represent a large group among the
inborn errors of metabolism. The most frequently observed biochemical defect is isolated deficiency of
mitochondrial complex I (CI). No effective treatment strategies for CI deficiency are so far available. The purpose of
this study was to investigate whether and how mesenchymal stem cells (MSCs) are able to modulate metabolic
function in fibroblast cell models of CI deficiency.
Methods: We used human and murine fibroblasts with a defect in the nuclear DNA encoded NDUFS4 subunit of
CI. Fibroblasts were co-cultured with MSCs under different stress conditions and intercellular mitochondrial transfer
was assessed by flow cytometry and fluorescence microscopy. Reactive oxygen species (ROS) levels were measured
using MitoSOX-Red. Protein levels of CI were analysed by blue native polyacrylamide gel electrophoresis (BN-PAGE).
Results: Direct cellular interactions and mitochondrial transfer between MSCs and human as well as mouse
fibroblast cell lines were demonstrated. Mitochondrial transfer was visible in 13.2% and 6% of fibroblasts (e.g.
fibroblasts containing MSC mitochondria) for human and mouse cell lines, respectively. The transfer rate could be
further stimulated via treatment of cells with TNF-α. MSCs effectively lowered cellular ROS production in NDUFS4-
deficient fibroblast cell lines (either directly via co-culture or indirectly via incubation of cell lines with cell-free MSC
supernatant). However, CI protein expression and activity were not rescued by MSC treatment.
Conclusion: This study demonstrates the interplay between MSCs and fibroblast cell models of isolated CI
deficiency including transfer of mitochondria as well as modulation of cellular ROS levels. Further exploration of
these cellular interactions might help to develop MSC-based treatment strategies for human CI deficiency.
Background
Mitochondria are important cell organelles involved in
many biological processes such as aerobic metabolism of
glucose and fat, calcium signalling and apoptosis regula-
tion [1–3]. Among the metabolic pathways located within
mitochondria, oxidative phosphorylation (OXPHOS) plays
a prominent role in cellular energy homeostasis. The
system consists of four multi-protein complexes (CI–CIV)
and the F0F1-ATP synthase (CV), embedded in the inner
mitochondrial membrane [4, 5]. Disorders of the OXPHOS
system can lead to a wide range of human diseases (e.g.
Leigh disease, MELAS, LHON, MERRF, etc.), frequently af-
fecting multiple organs. They can manifest at any age, with
various modes of inheritance, and the number of genetically
characterized OXPHOS diseases is constantly increas-
ing [1, 6]. Mitochondrial CI (NADH:ubiquinone oxido-
reductase) is the largest OXPHOS complex and
constitutes one of the entry points for electrons into
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the electron transport chain. It consists of 44 different sub-
units, of which 37 are encoded by nuclear DNA (nDNA)
and seven by mitochondrial DNA (mtDNA) [7, 8]. Among
these subunits, the nuclear encoded NADH dehydrogen-
ase ubiquinone Fe-S protein 4 (NDUFS4) is one of the
most evolutionary conserved subunits, which is required
for CI stability and function. Mutations within the
NDUFS4 gene are an important cause of early-onset Leigh
syndrome [9–12]. Until now, treatment options for mito-
chondrial diseases are mainly supportive and no curative
therapeutic approach is available for affected individuals.
Bone marrow-derived mesenchymal stem cells (MSCs)
were discovered in 1966 [13] and 4 years later MSCs
were isolated for the first time [14]. In the following
years, based on their biological properties, MSCs
emerged as a promising tool for cell-based treatment
strategies for various human diseases—for example
autoimmune disorders [15], osteopetrosis [16] and
Alzheimer’s disease [17]. One prominent example for
clinical application of MSCs is acute graft-versus-host
disease (GVHD) during allogeneic stem cell transplant-
ation [18]. The cellular effects of MSCs are partially re-
lated to immunosuppressive and immunomodulation
effects on innate and adaptive immune cells and they es-
cape recognition by alloreactive T cells [18, 19]. MSCs
have been reported to exert beneficial effects on many
other cell types. Several studies demonstrated that these
effects are dependent on paracrine mechanisms, includ-
ing secretion of microvesicles and exosomes [20, 21]. It
was shown that MSCs have the ability of intercellular or-
ganelle transport (including mitochondria) via thin
(diameter 50–200 nm) cytoplasmic bridges, named tun-
nelling nanotubes (TNTs), or via microvesicles [3, 22,
23]. The length of TNTs can be as long as the diameter
of several cells. They contained F-actin, allowing a direct
communication between distant cells. TNTs are dynamic
structures that can be formed within a few minutes, but
are fragile and highly sensitive to shearing forces and
chemical fixatives [23, 24].
In the present study, we investigated the influence of
MSCs on OXPHOS function in different cell culture
systems of isolated CI deficiency caused by knockout or
mutation of the NDUFS4 gene. We demonstrate that
MSCs can actively transport mitochondria to fibroblast
cell lines. However, in human as well as mouse fibroblast
cell lines this transfer was relatively low under resting
conditions. Transfer efficiency was increased moderately
by stimulation of the cells with TNF-α. The use of OPA1
knockout cells, which have a defect in mitochondrial fu-
sion, suggested that mitochondrial transfer between
MSCs and fibroblasts per individual cell is underesti-
mated in cell lines with normal mitochondrial dynamics.
We show that although mitochondrial transfer was ob-
served, reduced CI expression and function were not
rescued. However, measurements of mitochondrial re-
active oxygen species (ROS) levels indicated a positive
effect of mitochondrial transfer on oxidative stress. Be-
cause the use of MSC-derived cell-free culture medium
also mitigated ROS production, we conclude that MSCs
display effects on cellular redox homeostasis independ-
ent of mitochondrial transfer.
Methods
Cells and culture conditions
We used MSCs of the mouse strain C57BL/6 (Life Tech-
nologies). The mouse mesenchymal stem cells (mMSCs)
were plated on T75 flasks (Greiner bio-one) in Dulbec-
co’s Modified Eagle Medium/Nutrient Mixture F-12
(DMEM/F12; Gibco by life technologies) with Gluta-
MAX™-I (Gibco by life technologies) supplemented with
10% (v/v) fetal bovine serum (MSC FBS, qualified for
mesenchymal stem cells; Gibco by life technologies) and
1% penicillin–streptomycin (5000 U/ml; Gibco by life
technologies).
Human mesenchymal stem cells (hMSCs) were iso-
lated as follows: 5–20 ml of heparinized human bone
marrow aspirate was obtained from healthy volunteer
donors after informed consent (this was approved by the
local ethical committee of the Heinrich-Heine-University
Düsseldorf; study number #1830). The collected sample
were treated with red cell lysis buffer (155 mM ammo-
nium chloride, 10 mM potassium hydrogencarbonate,
0.1 mM Na2EDTA · 2H2O; provided by the Hospital Phar-
macy, University Clinic Düsseldorf, Germany) at a ratio of
1:2 and incubated for 10 min at room temperature. After
washing with HBSS (Lonza), cells were re-suspended in
complete medium consisting of Dulbecco’s Modified Eagle
Medium low glucose (Lonza), 2 mM glutamin (Lonza),
1 IE/ml Na-heparin (Ratiopharm), 5% human fresh or fro-
zen plasma and 5% platelet lysate (both provided by the
Institute of Hemostasis and Transfusion Medicine, Uni-
versity Clinic Düsseldorf, Germany), and transferred at a
density of ≤106 WBC/cm2 into T175 flasks (Corning).
Cells were cultured at 37 °C under 10% CO2 using a hu-
midified incubator (Binder). Cells were allowed to adhere
to the plastic surface for 24 h and then the medium was
replaced. The removed supernatant containing non-
adherent cells was transferred into new T175 flask and
after further 24 h the supernatant with non-adherent cells
was replaced by complete medium. When the cultures
reached approximately 70–80% confluence, adherent
cells were detached by treatment with TrypLE (Invi-
trogen) and re-plated into tissue flasks (all from
Corning) for further passages. For experiments,
hMSCs of passage 1–3 were used. The multipotenti-
ality of the MSCs was verified with the use of in-
vitro assays to differentiate MSCs into adipocytes
(StemPro Adipogenesis Differentiation Kit; Gibco)
Melcher et al. Stem Cell Research & Therapy  (2017) 8:150 Page 2 of 14
and chondrocytes (type II collagen staining according
to the protocol of PromoCell).
Primary human skin fibroblasts (NHDF-neo, Lot Num-
ber 7 F3956, 0000476623 and 0000478986; Lonza) and
wild-type (WT) mouse fibroblasts [9] were used as control
cell lines in the experiments described in the following.
Cell culture model systems of NDUFS4 deficiency in-
cluded an established immortalized embryonic mouse
fibroblast cell line [9], which has a knockout of NDUFS4
(NDUFS4 KO) [1], and a primary human skin fibroblast
cell line from a patient with a homozygous nonsense mu-
tation c.20C >G; p.(Ser7*) in NDUFS4 (NM_002495.2).
The use of these cell lines for this study was approved by
the local ethical committee of the Heinrich-Heine-
University Düsseldorf (study number #4272). In patient fi-
broblasts, NDUFS4 protein was undetectable and CI activ-
ity was drastically reduced (see Additional file 1).
For additional control experiments, we obtained im-
mortalized embryonic mouse fibroblasts from the Insti-
tute of Biochemistry and Molecular Biology I (Medical
Faculty, Heinrich-Heine-University Düsseldorf ), which
have a knockout of the mitochondrial inner membrane
fusion protein optic atrophy 1 (OPA1 KO). All fibro-
blasts cell lines were cultured in DMEM with Gluta-
MAX™-I (Gibco by life technologies) supplemented with
10% FBS and 1% penicillin–streptomycin (5000 U/ml).
After fluorescence labelling via transduction, all cell lines
were cultured in selection medium (3 μg/ml blasticidin;
Gibco by life technologies). The medium was replaced
every 2–3 days, cells were split when the desired conflu-
ence (70–90%) had been reached and the experiments
started at the earliest 2 weeks after transduction.
Co-culture experiments
Fibroblasts and MSCs from the same species were co-
cultured in stem cell medium without blasticidin. For drug
treatment experiments, cells were co-cultured on six-well
plates (9.6 cm2 per well; Greiner CELLSTAR). For ROS
measurements and fluorescence microscopy, cells were
co-cultured on glass-bottom dishes (27 mm; Nunc by
Thermo Fisher Scientific). Stem cells and fibroblasts were
co-cultured in a ratio of 2:1 (drug treatment experiments)
and in a ratio of 1:1 (ROS measurements and fluorescence
microscopy) for 72 h in a humidified atmosphere (95% air,
5% CO2) at 37 °C.
Drug treatment
Galactose (Gal), 2-deoxy-D-glucose (2DG), D,L-buthionine-
(S, R)-sulfoximine (BSO) and tumour necrosis factor alpha
(TNF-α) were obtained from Sigma-Aldrich. The fibro-
blasts were pre-treated for 72 h (Gal) or 24 h (BSO, 2DG).
DMEM without Glucose (Gibco by life technologies) sup-
plemented with 10% FBS and 1% penicillin–streptomycin
(5,000U/ml) was used for the drug treatment experiments.
TNF-α was added to the cells during the co-culture. The
following concentrations were used: 5.5 mM Gal, 20 mM
2DG, 1 mM and 100 μM BSO, and 0.5, 1.0, 1.5 and 15 μg/
ml TNF-α.
SDS-PAGE and western blot analysis
First, mitochondria were isolated as described previously
[25] and the protein concentration was determined
(Pierce™ BCA Protein Assay Kit; ThermoFisher scien-
tific). Then, proteins were separated by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
on 4–12% protein gels (NuPAGE™ Novex™ 4–12% Bis–
Tris protein gels; Invitrogen). Gels were transferred to
0.2 μm nitrocellulose membrane (1 h at 200 mA; Bio-
Rad). Membranes were blocked and incubated with pri-
mary antibodies (anti-NDUFS4 (Sigma-Aldrich), poly-
clonal, 1:1000; voltage-dependent anion channel (VDAC;
Cell Signaling), monoclonal, 1:1000; or anti-SDHA
(Mitosciences MS204), 1:1000) overnight at 4 °C. Horse-
radish peroxidase-linked anti-mouse IgG antibody
(1:1000; GE Healthcare) or anti-rabbit IgG (1:1000; GE
Healthcare) were used as secondary antibodies.
Preparation of MSC supernatants
The MSC supernatant preparation was performed with
some modifications as described previously [21]. Briefly,
medium (supernatant) from MSCs was collected and cen-
trifuged at 300 × g for 10 min to remove the remaining
cells. Subsequently, the supernatant was transferred to a
new tube and centrifuged at 2000 × g for 10 min. The cell
and cell debris-free supernatant was then added to the fi-
broblasts. Every 24 h, fresh cell-free MSC supernatant was
added to the fibroblasts over a period of 72 h.
Fluorescent labelling
The sequences of the organelle markers Cox8a (Cyto-
chrome c oxidase subunit 8A) GFP, Cox8a RFP, LMNB
(Lamin B1) RFP and LMNB BFP were amplified from
pENTR plasmids from OriGene. A start and stop codon
was added by polymerase chain reaction (PCR). Open
reading frames of organelle markers were subcloned in
pLenti6.3/V5-TOPO Vector using the pLenti6.3/V5-
TOPO TA Cloning Kit (Invitrogen). Stable cell lines
from hMSCs and mMSCs with green fluorescent
mitochondria (Cox8a GFP) and from human and mouse
fibroblasts with red fluorescent mitochondria (Cox8a
RFP) and red or blue fluorescence nucleus (LMNB RFP
or LMNB BFP) were produced by lentiviral transduction.
Transduction was performed according to the manufac-
turer’s protocol with some modifications. Briefly, HEK-
293 T cells (HEK-T) were seeded in T75 flasks (1 × 106
cells/ flask) in DMEM with 10% FBS. After 24–48 h the
HEK-T had reached a confluence of 70% and the
medium was changed to 5 ml OptiMEM (Gibco by life
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technologies). A mixture of the plasmids (pLenti6.3/V5
+ insert and packing plasmids) and Lipofectamin 2000
(Invitrogen) in OptiMEM was added to the HEK-T. The
medium was replaced after 24 h by DMEM with 10% FBS
passed through a 0.45-μM Millex-HV filter (Merck
Millipore). Again 24 h later, the supernatant from the
HEK-T was added to the cells to be transduced (mMSCs,
MSCs, fibroblasts). Using a high-speed sorter (MoFlo
XDP; Beckman-Coulter), the cells were highly enriched
(RFP, GFP or BFP positive) 2 weeks after transduction.
Fluorescence imaging of mitochondrial transfer
After co-culturing, cells were stained with phalloidin
(mouse cells with Alexa Fluor 594, human cells with
Alexa Fluor 650 phalloidin; Molecular Probes). First,
cells were fixed for 20 min in the dark with formalin,
washed with PBS and permeabilized with 0.3% triton in
PBS. Then, cells were incubated for 20 min with phal-
loidin. Images were obtained by fluorescence microscopy
(40× objective; Zeiss; Axio Observer Z1 microscope with
ApoTome 2 and a Perkin-Elmer Ultra View spinning
disc confocal microscope) equipped with a GFP filterset
(excitation: 520/28 BrightLine HC, emission: 482/18
BrightLine HC; AHF Analysetechnik), DAPI HC BrightLine
Basic filterset BFP (excitation: 390/18 BrightLine HC, emis-
sion: 460/60 BrightLine HC; AHF Analysetechnik), Filterset
31 (excitation: BP 565/30, emission: BP 620/60; Zeiss) and
Filterset 50 (excitation: BP 640/30, emission: BP 690/50;
Zeiss). For live cell microscopy with recording of time-lapse
videos (see Additional files 4 and 5), images were acquired
at intervals of 30 sec for a duration of 8 min.
Measurements of ROS levels
The measurements of cellular ROS production were per-
formed with some modifications as described previously
[5]. Briefly, after co-culture for 72 h, cells were incubated
with MSC medium containing MitoSOX Red (5 μM,
10 min, 37 ° C; Invitrogen). The red fluorescence was
documented using an Axio Observer Z1 microscope
(Zeiss) with the dehydroethidium filterset (F39-500, F48-
515, F47-895; AHF Analysetechnik). Images were
analysed and fluorescence intensity was quantified using
ImageJ software (Wayne Rasband at the National Insti-
tutes of Health; http://rsbweb.nih.gov/ij/).
Quantification of mitochondrial mass
Mitochondrial mass was determined as described previ-
ously with some modifications [26]. We used Cox8a-
labelled fibroblasts and Cox8a-labelled MSCs for this
experiment.
Analysis of mitochondrial transfer by flow cytometry
After co-culture (24, 48 or 72 h), cells were detached
with TrypLE select (Gibco by life technologies), washed
with PBS and fixed with Fixation Buffer (BioLegend) for
20 min in the dark. Subsequently the probes were washed
again with PBS and finally re-suspended in 100 μl PBS. A
FACS Canto-II flow cytometer (BD Bioscience) was used
for the measurements and data analysis was performed
using FlowJo software version 10. Fibroblasts and stem
cells were distinguished by their different fluorescence
labelling. Only the mitochondria transfer from stem cells
to fibroblasts was quantified. Approximately 30,000 cells
were evaluated for each sample.
Blue native polyacrylamide gel electrophoresis
Blue native polyacrylamide gel electrophoresis (BN-
PAGE) was performed according to a previously de-
scribed standard protocol [27] with slight modifications.
In brief, mitochondria-enriched cell fractions were gen-
erated by re-suspending cell pellets in 2% digitonin
followed by centrifugation. These fractions were re-
suspended in 2% n-dodecyl β-D-maltoside to solubilize
membrane proteins. Then 100 μg of mitochondrial pro-
tein was loaded for each sample and separated on a 4–
12% BN-PAGE gradient gel. After BN-PAGE, gels were
subjected to western blotting and immunodetection as
already described. Complex I in-gel-activity assay was
performed by incubating the blue native gel with com-
plex I IGA solution (3 mM nitrotetrazolium blue,
150 μM NADH, 2 mM Tris–HCl, pH 7.4) for 2 h at
room temperature immediately after the gel run. After
briefly washing the gel with ultrapure water, images of
the gel were captured using a gel scanner (Image Scan-
ner III; GE Healthcare).
Measurement of complex I enzyme activity
Cells were cultured for 72 h with or without supernatant
from MSCs. Activity of complex I was measured using a
complex I enzyme activity microplate assay kit (Abcam)
according to the manufacturer’s protocol.
Statistical analysis
Unless otherwise described, experimental data are shown
as mean ± standard error of the mean (SEM) or standard
deviation and the statistical significance between datasets
is assessed using an independent two-population Student’s
t test. p < 0.05 was considered significant. All statistical
analysis was performed using GraphPad Prism 7.
Results
MSCs transfer mitochondria to fibroblasts with NDUFS4
deficiency
Mitochondrial transfer via TNTs in vitro has already
been described for some cell types—for example be-
tween endothelial cells and cancer cells [28], between rat
renal tubular cells and MSCs [29] and between cardio-
myocytes and MSCs [22]. However, this phenomenon
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was not analysed in nuclear DNA encoded CI defects.
Moreover, studies suggest that mitochondrial transfer
might only be relevant in cell models with near total
absence of mitochondrial function and does not play
a role in human diseases caused by mitochondrial
dysfunction [30].
To investigate whether MSCs are able to transfer
mitochondria in two model systems of mitochondrial
NDUFS4 deficiency (e.g. patient-derived fibroblasts with
pathogenic NDUFS4 mutations and mouse fibroblast
with NDUFS4 knockout), we performed co-culture stud-
ies of MSCs with fibroblast cell lines. For visualization,
MSC mitochondria were labelled with Cox8a GFP and
fibroblast mitochondria with Cox8a RFP or the nuclei
with LMNB BFP. After co-culture, cell boundaries were
additionally stained with phalloidin, which binds to actin
filaments. Next, cell cultures were examined by fluores-
cence microscopy. Video imaging studies of living cells
as well as confocal microscopy studies indicated the for-
mation of thin cytoplasmic bridges between the different
cell lines, which most likely represent actin filament-
based TNTs. Moreover, for human and mouse cell lines,
we observed transfer of mitochondria between MSCs
and fibroblasts (Fig. 1a, b; see also Additional files 2 and
Fig. 1 a, b Mitochondrial transfer from MSCs to fibroblast cell lines. a Representative fluorescence images showing mitochondrial transfer and
TNT formation. Mitochondria of stem cells are labelled with Cox8a GFP (green fluorescent protein), mitochondria of human fibroblasts are
labelled with Cox8a RFP (red fluorescent protein) and nuclei of murine fibroblasts are labelled with LMNB BFP (blue fluorescent protein). Co-
cultures were fixed and stained with phalloidin. b Confocal images of mitochondrial transfer derived from MSCs. Fibroblast mitochondria are la-
belled with Cox8a RFP and stem cell mitochondria are labelled with Cox8a GFP. c, d Representative fluorescence images of cell fusion between
stem cell and fibroblast. c Mitochondria are labelled with Cox8a GFP (stem cell) and Cox8a RFP (fibroblast). Cells with a complete co-localization of
red and green fluorescence indicate the rare event of nuclear fusion (yellow cells). d Stem cells have Cox8a GFP-labelled mitochondria and LMNB BFP-
labelled nuclei. Fibroblasts have LMNB RFP-labelled nuclei. Cells with a co-localization of LMNB BFP and LMNB RFP have fused nuclei. Scale bars repre-
sent 10 μm. Images were contrast optimized (Colour figure online). Cox8a Cytochrome c oxidase subunit 8A, LMNB Lamin B1
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3 as well as the time-lapse videos in Additional files 4
and 5). Of note, this appeared not to be a unidirectional
transfer but also occurred from fibroblasts to MSCs.
In addition to the transfer of isolated/small amounts
of mitochondria we also identified cells with complete
co-localization of MSC and fibroblast mitochondria (e.g.
a yellow mitochondrial network; Fig. 1c). These findings
suggested cellular or even nuclear fusion. To further
investigate the phenomenon, we labelled MSC nuclei
with LMNB BFP and mitochondria with Cox8a GFP and
the fibroblast nuclei with LMNB RFP. As depicted in
Fig. 1d, we observed a complete co-localization of MSC
and fibroblast nuclei (Fig. 1d). This suggests complete
cellular and nuclear fusion. However, at less than 0.1%,
the complete cell fusion appeared to be an extremely
rare phenomenon (data not shown).
TNF-α increases the efficiency of mitochondrial transfer
The amount of mitochondrial transfer was determined
by flow cytometry using LMNB RFP-labelled fibroblasts
and Cox8a GFP-labelled MSCs. After co-cultivation, a
subpopulation was observed, which was LMNB RFP and
Cox8a GFP positive. Next, we determined after which
time period (48, 72 or 96 h) the transfer rate between
patient and hMSCs or between NDUFS4 knockout and
mMSCs was most efficient (for illustration of the
method used, see also Additional file 3). As depicted in
Fig. 2a, transfer appeared optimal after 72 h (human
13.2% and mouse 6%). For this reason, we chose for all
further co-culture experiments a time period of 72 h. Of
note, we observed slight differences between the human
and the murine model systems. For example, in the mur-
ine system mitochondrial transfer between NDUFS4
knockout cells and control fibroblasts was rather low
(1–2%), but in the human system the transfer between
patient and control fibroblasts is almost as frequent as
between patient fibroblasts and MSCs.
As shown in Fig. 2a, transfer efficiency in both model
systems was relatively low. However, low transfer rate
might be influenced by cell culture conditions (e.g.
standard fibroblast culture provides optimal metabolic
supply, which potentially masks the OXPHOS defect).
Therefore, our hypothesis was that metabolic or oxida-
tive stress might increase mitochondrial transfer.
To stimulate transfer, fibroblasts were subjected to
stress condition by culturing in galactose medium as
well as BSO and 2DG treatment (Fig. 2b). Galactose is a
frequently used metabolic stress treatment, increasing
the dependence on OXPHOS-linked ATP production
[31]. BSO inhibits the glutamate cysteine ligase, which is
Fig. 2 Quantitative FACS measurement of mitochondrial transfer. a Flow cytometry analysis was performed after 48, 72 and 96 h of co-culture. Co-cultures
between MSCs and fibroblasts and between fibroblasts and fibroblasts (e.g. healthy controls with NDUFS4-deficient cell lines) were measured. b Mitochondrial
transfer during different culture conditions/drug treatment.mMSC mouse mesenchymal stem cell, MSCmesenchymal stem cell, Gal galactose medium, BSO
buthioninesulfoximine, 2DG 2-deoxy-D-glucose, TNF-α tumour necrosis factor alpha, NDUFS4 NADH dehydrogenase ubiquinone Fe-S protein 4, WT wild type.
Data shown as mean (% of “mito-positive” cells per measurement) ± SD. *p< 0.05, **p< 0.01, ***p< 0.001
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the rate limiting factor for glutathione synthesis. Gluta-
thione is an important cellular antioxidant. By inhibition
of the glutamate cysteine ligase, cells are exposed to oxi-
dative stress [32]. 2DG is a glucose analogue that par-
tially inhibits glycolysis, thereby reducing glycolytic flux.
This inhibition occurs by its action on hexokinase, which
is the rate limiting step of glycolysis [33].
As depicted in Fig. 2b, culturing in galactose medium
and BSO treatment did not alter transfer efficiency in
both model systems. Interestingly, 2DG treatment mod-
erately increased mitochondrial transfer between human
control fibroblasts and hMSCs.
Next, we evaluated the effects of TNF-α treatment in
the different cell lines. TNF-α is known to stimulate the
formation of TNTs by remodelling of actin filaments
[34]. As shown in Fig. 2b, TNF-α dose-dependently stim-
ulated transfer efficiency with significant effects at a rela-
tively high concentration of 15 ng/ml between human
patient fibroblasts and hMSCs (10.1% ± 2.1 without
TNF-α and 16.3% ± 2.9 with 15 ng/ml TNF-α) and
between NDUFS4 KO and mMSCs (5% ± 0.8 without
TNF-α and 7.4 ± 1.2 with 15 ng/ml TNF-α).
Abrogating mitochondrial fusion indicates transfer of
more mitochondrial mass per individual cell
Even during the aforementioned TNF-α treatment, the ef-
ficiency of mitochondrial transfer appeared to be relatively
low. However, mitochondria are dynamic organelles,
which constantly go through the fission/fusion cycle.
Therefore, it might be possible that transferred mitochon-
dria rapidly fuse with the mitochondrial network of the
“host cell” so that the fluorescence signal is diluted and
thereby the transfer rate could be underestimated. For this
reason, mMSCs were co-cultured with a murine OPA1
KO cell line. The OPA1 protein is essential for mitochon-
drial fusion and cells without functional OPA1 have a
fragmented mitochondrial network that is unable to in-
corporate/fuse mitochondria [35]. For the experiments
depicted in Fig. 3a, the nuclei of the OPA1 KO fibroblasts
were labelled with LMNB RFP and the mMSC mito-
chondria were labelled with Cox8a GFP. Transfer was
analysed by flow cytometry after co-cultivation for
72 h. A higher transfer rate between OPA1 KO fibro-
blast and mMSCs could not be detected (e.g. no in-
crease in the double-stained cell population; Fig. 3a).
To investigate the mitochondrial transfer on the sin-
gle cell level, OPA1 KO mitochondria were labelled
with Cox8a RFP and mMSC mitochondria with Cox8a
GFP. Using confocal microscopy, we observed that,
despite the earlier findings, larger amounts of mMSC
mitochondria were transferred to OPA1 KO fibro-
blasts per single cell (Fig. 3b). This suggests that the
images depicted in Fig. 1 potentially under-represent
mitochondrial transfer because of incorporation into
the mitochondrial network of the acceptor cell or be-
cause of degradation via autophagy/mitophagy. Inter-
estingly, analysis of the mitochondrial mass in human
and mouse NDUFS4-deficient fibroblasts revealed that
cells with uptake of MSC mitochondria had a significant
increase in mitochondrial mass (Fig. 3c). This argues
against the idea that only single mitochondria are trans-
ferred and speaks against the hypothesis that transferred
mitochondria are rapidly degraded via autophagy.
MSCs exert antioxidative effects on NDUFS4-deficient
fibroblasts
Mitochondria are a major source of cellular ROS pro-
duction via the process of OXPHOS (in particular via CI
and CIII) [36]. This phenomenon might be aggravated
under conditions of OXPHOS dysfunction. In fibroblasts
of patients with nuclear encoded CI deficiency it was
shown that superoxide production as well as hydrogen
peroxide levels are significantly elevated [37].
Using the fluorescent probe MitoSOX Red, measure-
ments of mitochondrial ROS levels were carried out via
live-cell microscopy. For this analysis, stem cell mito-
chondria were labelled with Cox8a GFP and the nuclei
of NDUFS4-deficient fibroblasts were labelled with
LMNB BFP. Using this approach, we were able to meas-
ure NDUFS4-deficient fibroblasts with and without
mitochondrial transfer on the same coverslip.
Results in human cell lines demonstrated increased
ROS levels in NDUFS4-deficient fibroblasts (Fig. 4a, upper
panel). After co-cultivation of human fibroblasts with
hMSCs, the ROS levels in patient fibroblasts that had re-
ceived hMSC mitochondria normalized. Figure 4c shows a
representative fibroblast with transferred mitochondria
from MSCs (green) and the MitoSOX staining (red). How-
ever, we also observed that patient fibroblasts without ob-
vious mitochondrial transfer showed lower ROS levels
compared with untreated conditions. This finding suggests
that apart from direct mitochondrial transfer, additional
factors (e.g. paracrine factors, microvesicles, etc.) might
play a role during co-culture conditions.
Similar findings were obtained when studying the
mouse cell model system (Fig. 4a, lower panel). Of note,
ROS levels in mouse NDUFS4 KO cells were only ele-
vated under low-glucose culture conditions and normal-
ized under high-glucose conditions, which suggests
differences in cell metabolism compared with primary
human cells.
To investigate the effects of MSCs independent of
mitochondrial transfer, we cultured fibroblasts with stem
cell medium supernatant, which was free of stem cells
and cell debris. To this end, every 24 h the supernatant
was replaced by fresh supernatant and after 72 h we
measured ROS levels using MitoSOX Red. Fibroblasts
treated with stem cell supernatant produced significantly
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less ROS compared with untreated fibroblasts (Fig. 4b).
This supports the earlier idea that MSC-derived factors
are released into the cell culture medium to modulate
biological functions of other cell types.
Mitochondrial transfer and mitigation of cellular ROS
production are unable to rescue CI deficiency in NDUFS4-
deficient fibroblasts
The NDUFS4 subunit was not detectable in patient fibro-
blasts and in murine NDUFS4 KO fibroblasts (see Add-
itional file 1A). CI activity of NDUFS4-deficient patient
fibroblasts was less than 10% of the average mean in con-
trol cells. Without the NDUFS4 subunit CI is very un-
stable, which results in a reduced activity in NDUFS4-
deficient fibroblasts [38]. To check whether treatment of
fibroblasts with MSC supernatant leads to an increase of
fully assembled CI, BN-PAGE was performed. Even after
72 h of treatment no assembled CI or CI in-gel activity
could be detected in NDUFS4-deficient fibroblasts, neither
in the mouse nor the human system (Fig. 5). Similar find-
ings were obtained using a complex I enzyme activity mi-
croplate assay in mouse fibroblasts (Fig. 5c). Secreted
factors of MSCs are not sufficient to increase CI levels of
the NDUFS4-deficient fibroblasts to a detectable level.
Discussion
Intercellular communication is an essential process for
the development and maintenance of multicellular
Fig. 3 Mitochondrial transfer between OPA1 KO fibroblasts and murine MSCs. a OPA1 KO fibroblasts were transfected with LMNB RFP (red fluorescent
protein) to label the nuclei and mMSCs were transfected with Cox8a GFP (green fluorescent protein) to label the mitochondria. Flow cytometry was
performed after 72 h co-culture. Data shown as mean (% of “mito-positive” cells per measurement) ± standard deviation. b Fluorescence images of
mitochondrial transfer. Mitochondria of OPA1 KO fibroblasts were transfected with Cox8a RFP and stem cell mitochondria were transfected with Cox8a
GFP. Scale bars represent 10 μm. Images were contrast optimized. c Mitochondrial mass was measured via live-cell microscopy in fibroblasts with and
without visible mitochondrial transfer from MSCs. A significant increase was detected in fibroblasts that received MSC mitochondria during co-cultivation.
*p< 0.05. n.s. not significant, mMSC mouse mesenchymal stem cell, MSC mesenchymal stem cell, NDUFS4 NADH dehydrogenase ubiquinone Fe-S protein
4, OPA1 optic atrophy 1, WT wild type (Colour figure online)
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organisms. The discovery of nanotube-mediated mem-
brane continuity between mammalian cells triggered a
renewed interest in cell–cell interactions [39]. Several
studies indicate that MSCs can affect the aerobic respir-
ation of neighbouring cells by TNT-mediated mitochon-
drial transfer [3]. The current study aimed to determine
whether mitochondrial transfer occurred from MSCs to
fibroblasts with mitochondrial dysfunction due to
NDUFS4 mutation (human cells) or knockout (mouse
cells).
We demonstrate that, under physiological conditions,
mitochondria are transferred from MSCs to fibroblasts
albeit at a relatively low efficiency (6–14%). Evidence
from the literature suggested that mitochondrial transfer
is increased by conditions of oxidative stress, during
conditions of metabolic stress and by TNF-α treatment.
Zhu et al. [40] analysed the effects of oxidative stress on
the F-actin fibres in astrocytes. They found that increas-
ing ROS levels via exogenous applications of H2O2 stim-
ulates the polymerization of actin and thus the
formation of TNT-like structures. Liu et al. [41] reported
a mitochondrial transfer rate of approximately 40% be-
tween MSCs and human umbilical vein endothelial cells
after oxygen glucose deprivation and subsequent reoxy-
genation (under normal conditions 8%). Ahmad et al.
[42] showed an increased transfer rate between mouse
Fig. 4 Mitochondrial ROS production was measured using MitoSOX Red (mitochondria-targeted superoxide indicator). a Fibroblast nuclei were labelled
with LMNB BFP (blue fluorescent protein) and stem cell mitochondria were labelled with Cox8a GFP. Only fibroblasts with a blue fluorescent nucleus were
measured. The measured fibroblasts were divided into two groups: fibroblasts with obviously transferred mitochondria derived from MSCs; and fibroblasts
without transferred mitochondria. b MitoSOX measurement was performed after 72-h treatment with stem cell supernatant or control cell supernatant.
Data shown as mean ± SEM. *p < 0.05, ***p < 0.001. c Representative fluorescence images showing a transferred MSC mitochondrion (green) in a
human fibroblast (blue nuclei). Mitochondrial MitoSOX fluorescence is shown (red). Scale bar represents 10 μm. mMSC mouse mesenchymal stem cell,
MSC mesenchymal stem cell, NDUFS4 NADH dehydrogenase ubiquinone Fe-S protein 4, ROS reactive oxygen species, WT wild type (Colour figure online)
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lung epithelial cells (LA4) and stem cells after stress
treatment with Rotenone.
Our model involving application of BSO, a substance
that reduces the glutathione pool and thereby raises
ROS levels, did not detectably increase mitochondrial
transfer. Similarly, induction of metabolic stress by gly-
colysis inhibition using 2DG or GAL treatment exerted
only minor (2DG) or no (GAL) effect on mitochondrial
transfer. Only TNF-α treatment dose-dependently stim-
ulated transfer efficiency with significant effects at a rela-
tively high concentration. This observation suggests that
MSCs respond particularly well to immunological stim-
uli. MSCs show immune homeostatic functions, which
are enhanced by the exposure of pro-inflammatory cyto-
kines, such as TNF-α [43]. High concentrations of TNF-
α trigger the F-actin polymerization and thereby the for-
mation of TNTs. This phenomenon most likely contrib-
utes to increased mitochondrial transfer from MSCs to
fibroblasts [44].
Of note, determining mitochondrial transfer is chal-
lenging because mitochondria are constantly involved
in the processes of fission and fusion. Mitochondrial
fusion can be stimulated by oxidative stress and de-
fective mitochondria may be complemented by diffu-
sion and exchange of components between organelles
[45]. Accordingly, transferred mitochondria may fuse
with the network of the acceptor cell and thereby “es-
cape” from measurements. Using an OPA1 KO cell
line, which is deficient for mitochondrial fusion, we
observed that individual OPA1 KO cells received
Fig. 5 a BN-PAGE with mitochondrial lysates from human and mouse fibroblasts cell lines shows no recovery of fully assembled complex I levels upon
treatment with MSC supernatant. Complex II SDHA was used as loading control. b Complex I in-gel-activity assay demonstrates no improvement of CI
activity upon treatment with MSC supernatant. c A complex I enzyme activity microplate assay kit was used to determine the complex I activity in mouse
NDUFS4 KO and WT fibroblasts treated or untreated with supernatant from mMSCs. In accordance with BN-PAGE analysis, no significant increase in activity
could be detected. Rate (mOD/min) = Absorbance 1 – Absorbance 2 / time (min). mMSC mouse mesenchymal stem cell, MSC mesenchymal stem cell,
NDUFS4 NADH dehydrogenase ubiquinone Fe-S protein 4, WT wild type
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larger amounts of mitochondria compared with what
we detected in other cell lines (e.g. more transferred
mitochondria per fibroblast; see Fig. 3b). However,
the overall transfer rate regarding the total cell popu-
lation was not increased compared with other mouse
fibroblast cell lines. This suggests that mitochondrial
transfer per cell might be underestimated in fibroblast
lines with normal mitochondrial dynamics. In general,
the fate of transferred mitochondria remains unclear.
Apart from fusion with the mitochondrial network of
the acceptor cell, it might also be possible that trans-
ferred mitochondria are rapidly degraded via mito-
phagy, which might in part be responsible for the low
detection rates of “mito-positive” fibroblasts. However,
the increase of mitochondrial mass in fibroblasts that
received mitochondria from MSCs suggests that in-
corporation into the mitochondrial network of the ac-
ceptor cell is the primary mechanism.
In view of the OXPHOS defect, the main question
certainly is to what extent cell contacts between
MSCs and fibroblasts with mitochondrial transfer are
beneficial for cell metabolism. Of note, dysfunction of
the OXPHOS system is known to alter mitochondrial
ROS production. As depicted in Fig. 4, levels of Mito-
SOX Red-oxidizing ROS were significantly increased
in NDUFS4-deficient cell lines under non-treated con-
ditions. Interestingly, in embryonic mouse fibroblasts,
this increase was only detectable when culturing the
cells in low-glucose medium, indicating that these
cells may compensate the metabolic problem in case
of high glucose supply [46]. After co-culture with
MSCs, we observed a clear reduction of ROS levels in
NDUFS4-deficient fibroblasts that received MSC
mitochondria. In human cell lines, ROS levels even
normalized completely. However, also in the “mito-
negative” cell population, we observed clear effects on
ROS levels indicating that the underlying mechanism
might not only be related to mitochondrial transfer.
This idea was further supported by the observation
that treatment with cell-free MSC culture medium
supernatant had similar effects on ROS levels.
MSCs are known to contain high levels of glutathione
[47]. Glutathione is a substrate for glutathione peroxid-
ase and other antioxidant enzymes, which represents a
crucial cellular protection system against oxidative stress
[48, 49]. Ayatollahi et al. [49] showed that oxidative
stress could be significantly reduced via MSCs in rats
with a carbon tetrachloride-induced liver damage. In
view of the presented results, it appears highly likely that
glutathione and/or other antioxidants are transferred to
the NDUFS4-deficient fibroblasts (most likely via mul-
tiple mechanisms including TNTs and microvesicles),
leading to the reduction in ROS levels. Modulation of
cellular redox homeostasis appeared to be specific for
MSCs and was not observed after co-culture/treatment
of NDUFS4-deficient fibroblasts with healthy control fi-
broblasts/control medium supernatant. In contrast,
mitochondrial transfer was not entirely MSC specific in
the human cell model system and was also visible after
co-culture of NDUFS4-deficient fibroblasts with control
fibroblasts.
Despite the aforementioned effects of MSCs on
redox homeostasis, it remains to be answered in how
far OXPHOS function can be improved in NDUFS4-
deficient fibroblasts via MSC treatment. However, for
analysis of mitochondrial CI expression and activity,
MSCs and fibroblasts need to be separated after co-
culture and a high purity of sorted cells is required.
Moreover, relatively large amounts of cells are neces-
sary. We were unable to achieve these experimental
conditions in our co-culture system. Based on the ob-
servation that treatment of fibroblasts with MSC
medium supernatant achieved similar effects on ROS
levels compared with co-culture, we proceeded with
analysing CI function in this experimental setting. As
depicted in Fig. 5, treatment of NDUFS4-deficient fi-
broblasts with MSC supernatant had no visible effects
on levels of fully assembled CI in human and mouse
cell lines.
Conclusions
This study clearly indicates cellular interactions and
mitochondrial transfer between MSCs and human as
well as mouse fibroblast cell lines. However, mitochon-
drial transfer appeared to be a relatively rare
phenomenon and the transfer rate could only be stimu-
lated moderately by TNF-α treatment. The fate and
functional relevance of transferred mitochondria
remained elusive. Moreover, mitochondrial transfer in
our cell culture systems was not entirely specific for
MSCs and was also observed between control and
patient-derived fibroblasts. In contrast, MSCs effectively
lowered cellular ROS levels in NDUFS4-deficient fibro-
blast cell lines. This appeared to be a phenomenon that
was at least partially independent of mitochondrial
transfer and is putatively mediated via secreted factors
(e.g. microvesicles). Modulation of cellular redox
homeostasis was MSC specific and could not be
achieved via control fibroblast cell lines. However, CI ex-
pression and activity could not be rescued by treatment
with MSC medium supernatant. In view of this observa-
tion and the relatively low mitochondrial transfer effi-
ciency during direct co-culture conditions, it appeared
unlikely that an MSC-based treatment approach in
NDUFS4-related CI deficiency directly enhances cellular
energy metabolism. Nevertheless, modulating and miti-
gating ROS production via MSCs may be an interesting
starting point for further in-vivo research studies
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involving established mouse models of mitochondrial
NDUFS4 deficiency.
Additional files
Additional file 1: (A) Western blot analysis from murine NDUFS4 KO
and WT cells and from human patient and human control cells. In
NDUFS4 KO cells and in NDUFS4-deficient patient cells, no NDUFS4
protein expression is detectable. VDAC (voltage-dependent anion
channel) used as loading control. (B) Biochemical measurements from
fibroblasts of the NDUFS4-deficient patient, demonstrating severe CI
deficiency. For details regarding methods that were used to measure
OXPHOS enzyme activities in fibroblasts [50]. (TIF 92 kb)
Additional file 2: (A) Representative fluorescence images showing a
mouse fibroblast with LMNB BFP-labelled nucleus, a mouse stem cell
(mMSC) with Cox8a GFP-labelled mitochondria and a mouse fibroblast
containing mitochondria derived from mMSCs. Cell boundaries are
stained with phalloidin. (B) Confocal image depicting a mouse fibroblast
with Cox8a RFP-labelled mitochondria in co-culture with an mMSC
containing Cox8a GFP-labelled mitochondria. (C) Representative confocal
images of human cells. Left: human fibroblasts with Cox8a RFP-labelled
mitochondria without transferred mitochondria (upper image) or after
mitochondrial transfer via hMSCs (lower image). Right: Cox8a GFP-labelled
hMSCs with Cox8a GFP-labelled mitochondria without transferred
mitochondria (upper image) or after mitochondrial transfer from human
fibroblasts (lower image). Scale bar represents 10 μm. (TIF 912 kb)
Additional file 3: (A) Mitochondrial transfer between mouse fibroblasts
and mMSCs. Representative fluorescence image of TNTs between
fibroblast and mMSC (white arrow). Scale bar represents 10 μm. (B)
Representative flow cytometry analysis images for analysing of
mitochondrial transfer. Gating procedure of LMNB RFP positive fibroblasts
with transferred Cox8a GFP positive MSC mitochondria. Black arrows
indicate sequential analysis steps. Cells (fibroblasts and MSCs) were
selected on the basis of cellular size (forward scatter area, FSC-A) and
granularity (side scatter area, SSC-A). Only LMNB RFP positive fibroblasts
were used for the next step. Cell doublets were excluded by comparing
SSC-H (side scatter height) and SSC-W (side scatter width). Double
positive fibroblasts were determined. (TIF 670 kb)
Additional file 4: Is a time-lapse video showing a NDUFS4-deficient
mouse fibroblast. Mouse fibroblast mitochondria are labelled (red, Cox8a
RFP). The fibroblast contains several green mitochondria (Cox8a GFP
labelled) which are derived from mMSCs. Please note the dynamic
motility of mitochondria during the time of video recording.
(AVI 1038 kb)
Additional file 5: Is a time-lapse video showing a NDUFS4-deficient
human fibroblast. Human fibroblast mitochondria are labelled (red, Cox8a
RFP). The fibroblast is in contact with a hMSC cell that appears to transfer
green mitochondria (Cox8a GFP labelled). Please note the dynamic motility
of mitochondria during the time of video recording. (AVI 1248 kb)
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